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For further details of this meeting please contact Suzanne Miller, 44 Roan Street, London SEIO 9JT. Telephone 0181 858 2699; fax 0181 853 4416; e-mail wight (ai compuserve.com. disease, and (b) what is the increase of probability provided by apoE genotyping? The table shows that in the series indicated by Roses and Saunders (see their table 1), the prior probability of patients with probable Alzheimer's disease ranges from 79 to 100%, and that the gain of apoE genotyping is between 0 and 21%. Furthermore, the gain of apoE genotyping in the group of patients in which additional information might be more useful-that is, possible Alzheimer's disease is not higher (12%). Therefore, the higher the accuracy of the clinical diagnosis of probable Alzheimer's disease, the lower the gain from apoE genotyping.
Another situation in which apoE might give additional diagnostic information is that of epidemiological studies (for example, prevalence studies or secondary prevention interventions on Alzheimer's disease in the community). In this case, apoE genotyping might increase the specificity of screening tools-that is, decrease the proportion of false positives. We have recently estimated that the false positive rate of the mini mental state examination (MMSE) as a screening test for Alzheimer's disease in the community would decrease from 13 to 7% by adding information on apoE genotype.4 This, in a hypothetical study carried out in a community of 1 000 000 with 7500 patients with Alzheimer's disease, with a sensitivity set at 99% translates into a decrease of false positive from 19 000 to 9500. The consequent cost savings might be relevant.
We think that the issue of the diagnostic gain is the central one in the cost/benefit analysis that must precede any diagnostic procedure. As for any medical service, the task of researchers is to accurately estimate costs and benefits. The individual purchaser of the service or society as a whole will then be able to judge whether or not the benefits are worth the cost. Oxford. 1996. ISBN 0-86542-874-3. There was a time when it was de rigour to start the review of a book on stroke with a preamble regretting the Cinderella status of stroke in the interests of neurologists. This was always a peculiarly British phenomenon and this book marks the triumphant fitting of Cinderella's slipper by the Prince, so far as stroke doctoring in the United Kingdom is concerned. Clinical medicine should always involve the application of science to the management of disease, science being a system of knowledge based on the evidence of observation and experiment, hence the tautological nature of the expression "evidence based medicine". Warlow and his colleagues have produced a book which is certainly the best book ever on stroke and must rate as one of the best of a new genre in medical publishing, a properly scientific treatise that is also of practical value in patient care. There is no statement whose evidential status is not carefully documented. The regrettable tradition of excathedra clinical dictates based on a mixture of guess work and blind tradition which is still so prevalent is nowhere to be seen in this book. Even the first chapter on the history of our knowledge of stroke displays an intellectual maturity (I suspect from van Gijn) not often seen in doctors writing about history. This is a chapter properly discussing
